Phillygenin-O-β-glucosaminide
Phillygenin-O-β-glucosaminide is an orally active Nrf2 inducer and NF-κB inhibitor that inhibits osteoclast differentiation and ROS production by promoting Nrf2 nuclear translocation, suppressing NF-κB and JNK phosphorylation, and downregulating NFATc1, c-Fos, MMP9, and CTSK expression. Phillygenin-O-β-glucosaminide can be used for research on osteoarthritis.
For research use only. We do not sell to patients.
- Formula: C27H35NO10
- Molecular Weight:533.57
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
Nrf2 |
NF-κB |
JNK |
MMP9 |
NFATc1 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| RAW264.7 | EC50 |
390.6 μM
|
Cytotoxicity against murine RAW264.7 cells assessed as reduction in cell viability incubated for 96 hrs.
Cytotoxicity against murine RAW264.7 cells assessed as reduction in cell viability incubated for 96 hrs.
|
42561561 |
| RAW264.7 | IC50 |
82.02 μM
|
Inhibition of RANKL and M-CSF-induced osteoclast differentiation in murine RAW264.7 cells.
Inhibition of RANKL and M-CSF-induced osteoclast differentiation in murine RAW264.7 cells.
|
42561561 |
In Vitro
Phillygenin-O-β-glucosaminide (compound 6) (50-800 μM; 24-96 h) exhibits dose-dependent activity in SW1353 and RAW264.7 cells[1].
Phillygenin-O-β-glucosaminide (200-800 μM; 24 h) attenuates oxidative stress and inflammatory injury in IL-1β-induced SW1353 chondrocytes by regulating the Nrf2 antioxidant pathway and the MAPK/JNK inflammatory pathway[1].
Phillygenin-O-β-glucosaminide (200-800 μM; 24 h) effectively promotes Nrf2 nuclear translocation in IL-1β-stimulated SW1353 cells[1].
Phillygenin-O-β-glucosaminide (50-200 μM; 4 days) inhibits osteoclast maturation in RAW264.7 cells at least partially through suppression of the NF-κB pathway[1].
Phillygenin-O-β-glucosaminide (50-800 μM; 96 h) exhibits low cytotoxicity in RAW264.7 cells with an EC50 of 390.6 μM[1].
Phillygenin-O-β-glucosaminide (50-200 μM) inhibits RANKL- and M-CSF-induced osteoclast differentiation in RAW264.7 cells with an IC50 of 82.02 μM[1].
Phillygenin-O-β-glucosaminide (1 μM) exhibits moderate plasma protein binding in human plasma[1].
Phillygenin-O-β-glucosaminide (45 min) is metabolically stable in human liver microsomes[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:SW1353 human chondrosarcoma cells
-
Concentration:50, 100, 200, 400, 800 μM
-
Incubation Time:24 h
-
Result:Exhibited dose-dependent anti-inflammatory activity.
-
Cell Line:RAW264.7 murine macrophage cells
-
Concentration:50, 100, 200, 400, 800 μM
-
Incubation Time:96 h
-
Result:Exhibited dose-dependent anti-osteoclast formation activity.
-
Cell Line:IL-1β-induced SW1353 human chondrosarcoma cells
-
Concentration:200, 400, 800 μM
-
Incubation Time:24 h
-
Result:Concentration-dependently upregulated the expression of collagen II and downregulated the expression of MMP13.
Markedly upregulated the expression of Nrf2 and HO-1, and downregulated the expression of p-JNK.
-
Cell Line:IL-1β-stimulated SW1353 human chondrosarcoma cells
-
Concentration:200, 400, 800 μM
-
Incubation Time:24 h
-
Result:Increased the nuclear-to-cytoplasmic ratio of Nrf2 fluorescence intensity in a concentration-dependent manner.
-
Cell Line:RAW264.7 murine macrophage cells
-
Concentration:50, 100, 200 μM
-
Incubation Time:4 days
-
Result:Concentration-dependently downregulated the expression of core osteoclast differentiation-related proteins, including NFATc1, c-Fos, MMP9, and CTSK.
Suppressed NF-κB pathway activation, as evidenced by reduced p-p65/p65 ratio and cleaved IL-1β levels.
-
Cell Line:RAW264.7 cells
-
Concentration:50, 100, 200, 400, 800 μM
-
Incubation Time:96 h
-
Result:Determined the EC50 value to be 390.6 μM.
Parmacokinetics
In Vivo
Phillygenin-O-β-glucosaminide (p.o.; single administration) distributes into the knee joint cavity after oral administration in rats, reaching a knee joint concentration of 264 ng/mL at 6 h, with a knee joint-to-plasma ratio of 4.52[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c mice (male, 8 weeks old)[1]
-
Dosage:50, 100, 200 mg/kg
-
Administration:i.g.; once daily; 30 consecutive days
-
Result:Improved grip strength in a dose-dependent manner.
Significantly improved grip strength compared to the combination group at 100 mg/kg.
Showed effects superior to diacerein groups at 200 mg/kg.
Significantly restored the mechanical pain threshold and outperformed phillyrin and the phillyrin-glucosamine combination in analgesic efficacy at 200 mg/kg.
Dose-dependently alleviated cartilage structural damage and inhibited matrix degradation, with efficacy comparable to the DIA-M group at 200 mg/kg.
Significantly reduced inflammatory cell infiltration and IL-6 levels compared to phillyrin and the combination group at 100 mg/kg.
Showed anti-inflammatory efficacy comparable to the DIA-M group at 200 mg/kg.
Dose-dependently inhibited osteoclast formation, with significantly fewer osteoclasts per site than phillyrin and the combination group at 100 mg/kg.
Significantly upregulated Nrf2 pathway proteins at 200 mg/kg.
Suppressed p-JNK at 100 mg/kg.
No significant toxicity was observed at doses up to 200 mg/kg for 30 days.
Chemical Information
-
Molecular Weight 533.57
-
Formula C27H35NO10
-
SMILES
COC1=CC=C([C@@H](OC[C@]23[H])[C@@]2(CO[C@H]3C(C=C4OC)=CC=C4O[C@H]5[C@H](N)[C@@H](O)[C@H](O)[C@@H](CO)O5)[H])C=C1OC
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Cytoplasmic-Nuclear Fractionated Protein Extraction
Cytoplasmic-nuclear fractionated protein extraction separates soluble cytoplasmic proteins from nuclear-enriched proteins by mild plasma-membrane permeabilization, differential centrifugation, washing of nuclei, and extraction of nuclear proteins for downstream immunoblotting or related molecular analysis. The readout is the relative abundance of a protein in cytoplasmic and nuclear fractions, commonly assessed by western blotting together with compartment markers such as tubulin or pyruvate kinase for cytoplasm and lamin, nucleoporin, hnRNP, H2AX, or Lamin B for nuclear fractions.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Osteoclast differentiation from monocyte/macrophage precursors
Osteoclast differentiation is an in vitro induction assay in which monocyte/macrophage-lineage precursors are exposed to macrophage colony-stimulating factor (M-CSF) and receptor activator of NF-κB ligand (RANKL), generating multinucleated osteoclasts that are commonly identified by tartrate-resistant acid phosphatase (TRAP) staining and functionally confirmed by resorption pits on dentin, bone, or mineralized substrates. M-CSF supports survival and expansion of osteoclast precursors, while RANKL binding to RANK drives osteoclast commitment, fusion, maturation, and resorptive function; osteoprotegerin inhibits this pathway by binding RANKL and preventing RANK activation. The main readouts are the number of TRAP-positive multinucleated cells, formation of F-actin rings, and resorbed surface area; TRAP-positive multinucleated cells indicate osteoclast differentiation, whereas pit formation on dentin, bone, or mineralized coating indicates functional bone-resorbing activity.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)